Search

Displaying results 3131 - 3140 of 10000 in total
  1. Drug

    Nazartinib

    go.drugbank.com/drugs/DB16250
    Investigational

    Nazartinib is under investigation in clinical trial NCT03529084 (Phase III Study of Nazartinib (EGF816) Versus Erlotinib/gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  2. Drug

    Vamorolone

    go.drugbank.com/drugs/DB15114
    ApprovedInvestigational

    [L48671,L48676] In December 2023, it was approved in the EU for the treatment of patients ≥4 years of age.[L49505] … [L48676] Vamorolone was approved by the FDA in October 2023 for the management of DMD in patients ≥2 years of age.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  3. Drug

    Imgatuzumab

    go.drugbank.com/drugs/DB14884
    Investigational

    Imgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With

  4. Drug

    Ceftobiprole

    go.drugbank.com/drugs/DB04918
    ApprovedWithdrawn

    The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion of ceftobiprole medocaril in February 2010, recommending the refusal of its marketing authorization in the European … Union primarily due to data quality issues in pivotal clinical studies.

    Categories: Heterocyclic Compounds, 2-Ring
  5. Drug

    Gefapixant

    go.drugbank.com/drugs/DB15097
    Approved

    [L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601] … It received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC, and received subsequent approval in the EU in September 2023 for the same indications.

    Categories: combinations of sulfonamides, MATE 1 Substrates
  6. Drug

    Grazoprevir

    go.drugbank.com/drugs/DB11575
    Approved

    In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Grazoprevir as first line therapy … in combination with [DB11574] for genotypes 1a, 1b, and 4 of Hepatitis C [A19593].

    Mixtures: ZEPATIER® TABLETAS RECUBIERTASCategories: Antivirals for treatment of HCV infections, P-glycoprotein substrates
  7. Drug

    Calcium glubionate anhydrous

    go.drugbank.com/drugs/DB13142
    Approved

    Calcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets.

    Synonyms: (D-gluconato)(lactobionato)calcium, Calcium D-gluconate lactobionateProducts: CALCIUM SANDOZ %10 AMPUL, 5 ADET, CALCIUM SANDOZ 10 ML 1,375 GR AMPUL, 5 ADET
  8. Drug

    Haemagglutinin-strain B (Victoria-like)

    go.drugbank.com/drugs/DB15473
    Approved

    Synonyms: Haemagglutinin-strain B (Victoria), Haemagglutinin-strain B (Victoria-like)Mixtures: Afluria Tetra Injektionssuspension in einer Fertigspritze
  9. Drug

    Abrocitinib

    go.drugbank.com/drugs/DB14973
    ApprovedInvestigational

    [L39784] On January 14, 2022, the FDA approved abrocitinib for the treatment of refractory, moderate-to-severe AD in adults whose disease is not adequately controlled with other systemic drug products, … [L39779] Health Canada also approved the use of abrocitinib in pediatric patients 12 years and older.[L42395]

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsProducts: CIBINQO® 100MG, CIBINQO® 50 MG
  10. Drug

    Ramoplanin

    go.drugbank.com/drugs/DB04952
    Experimental

    Ramoplanin is a novel glycolipodepsipeptide antibiotic under development for the treatment of CDAD.